Côme Lepage Selected Research

Colorectal Neoplasms (Colorectal Cancer)

4/2024	First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
10/2023	Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
1/2022	Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer.
1/2021	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.
10/2020	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
1/2020	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
1/2020	Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
10/2019	Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
3/2018	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).
1/2018	The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Côme Lepage Research Topics

Disease

16	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 03/2008
12	Neoplasms (Cancer) 01/2023 - 08/2013
7	Colonic Neoplasms (Colon Cancer) 10/2021 - 08/2014
5	Disease Progression 04/2024 - 02/2018
5	Neoplasm Metastasis (Metastasis) 01/2023 - 09/2014
4	Adenocarcinoma 04/2024 - 01/2015
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2023 - 01/2021
4	Hepatocellular Carcinoma (Hepatoma) 03/2021 - 11/2011
3	Neuroendocrine Carcinoma 01/2023 - 02/2018
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022 - 01/2020
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 03/2024 - 11/2014
2	Microsatellite Instability 10/2023 - 01/2021
2	Neutropenia 01/2023 - 03/2021
2	Asthenia 01/2023 - 03/2021
2	Inflammation (Inflammations) 12/2022 - 11/2021
2	Primitive Neuroectodermal Tumors (PNET) 01/2022 - 12/2021
2	Stomach Neoplasms (Stomach Cancer) 01/2022 - 01/2014
1	Ischemic Stroke 01/2023
1	Jaundice (Icterus) 01/2023
1	Anal Canal Carcinoma 01/2023
1	Alzheimer Disease (Alzheimer's Disease) 07/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 07/2022
1	Dementia (Dementias) 07/2022
1	Rectal Neoplasms (Rectal Cancer) 01/2022
1	Frailty 01/2022
1	Vipoma (WDHA) 12/2021
1	Liver Failure 03/2021
1	Thrombocytopenia (Thrombopenia) 03/2021
1	Hemorrhage 03/2021
1	Hypersensitivity (Allergy) 07/2019
1	Hyperbilirubinemia 11/2014
1	Complementation Group D1 Fanconi Anemia 08/2014
1	Diabetic Nephropathies (Diabetic Nephropathy) 04/2012
1	Fatty Liver 04/2012
1	False Aneurysm (Pseudoaneurysm) 09/2008

Drug/Important Bio-Agent (IBA)

7	Fluorouracil (Carac)FDA LinkGeneric 04/2024 - 08/2014
6	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2022 - 08/2014
5	PlatinumIBA 04/2024 - 02/2018
4	Leucovorin (Folinic Acid)FDA Link 04/2024 - 08/2014
3	Immune Checkpoint InhibitorsIBA 04/2024 - 01/2021
3	Irinotecan (Camptosar)FDA LinkGeneric 04/2024 - 01/2020
3	Bevacizumab (Avastin)FDA Link 01/2023 - 02/2018
3	Etoposide (VP 16)FDA LinkGeneric 01/2023 - 02/2018
3	Circulating Tumor DNAIBA 01/2022 - 01/2020
3	Sunitinib (Sutent)FDA Link 01/2022 - 03/2021
3	Gemcitabine FDA Link 01/2020 - 11/2014
3	Cisplatin (Platino)FDA LinkGeneric 07/2019 - 11/2014
3	Ethiodized Oil (Ethiodol)FDA Link 01/2018 - 11/2011
2	avelumabIBA 10/2023 - 01/2021
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2023 - 01/2023
2	ElementsIBA 12/2022 - 01/2022
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022 - 12/2021
2	Everolimus FDA Link 01/2022 - 12/2021
2	Cetuximab (Erbitux)FDA Link 10/2020 - 10/2018
2	Carboplatin (JM8)FDA LinkGeneric 07/2019 - 02/2018
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018 - 08/2013
2	Calcibiotic Root Canal SealerIBA 01/2018 - 08/2014
2	Dihydrotachysterol (AT 10)IBA 01/2015 - 03/2008
2	GuaiacIBA 12/2014 - 10/2008
2	AnthracyclinesIBA 08/2013 - 11/2011
1	afliberceptIBA 04/2024
1	durvalumabIBA 04/2024
1	tremelimumabIBA 04/2024
1	spleen fibrinolytic proteinase (human) (SFP)IBA 03/2024
1	Panitumumab (Vectibix)FDA Link 01/2023
1	InterferonsIBA 12/2022
1	Donepezil (Aricept)FDA LinkGeneric 07/2022
1	Cholinesterases (Cholinesterase)IBA 07/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	RamucirumabIBA 01/2022
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 12/2021
1	BilirubinIBA 03/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2021
1	Carcinoembryonic AntigenIBA 10/2020
1	Capecitabine (Xeloda)FDA Link 10/2020
1	chemotactic factor inactivatorIBA 01/2020
1	130-nm albumin-bound paclitaxelIBA 01/2020
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2020
1	SaltsIBA 07/2019
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 03/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	LIDAIBA 01/2018
1	EmulsionsIBA 01/2018
1	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 04/2012
1	AdiponectinIBA 04/2012
1	AdipokinesIBA 04/2012
1	Amiodarone (Amiodarona)FDA LinkGeneric 11/2011

Therapy/Procedure

19	Drug Therapy (Chemotherapy) 04/2024 - 10/2013
7	Therapeutics 01/2022 - 05/2016
5	Radiotherapy 11/2021 - 10/2013
4	Adjuvant Chemotherapy 10/2018 - 08/2014
2	Chemoradiotherapy 01/2023 - 11/2014
2	Induction Chemotherapy 10/2020 - 01/2020
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2023
1	Secondary Prevention 01/2022
1	Neoadjuvant Therapy 01/2022
1	Contraindications 01/2021
1	Adjuvant Chemoradiotherapy 01/2014
1	Time-to-Treatment 08/2013
1	Splenectomy 09/2008